ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pumitamig

Also written as “Pumitamig”, “PM8002” and “BNT327”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Breast Neoplasms · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 4 companies.

Drug pagePumitamig: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 14, 202434 company-led studies, 32 open or runningCo-development: BioNTech and Bristol Myers Squibb, Jun 2025Next primary completion: Jan 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTechits history only2321 open or runningphase 3since May 14, 2024Feb 15, 2023Jan 1, 2027phase 2 · NCT05879055
Bristol-Myers Squibbits history only99 open or runningphase 3since Oct 23, 2025Sep 26, 2024Mar 15, 2028phase 2 · NCT07871214
Boehringer Ingelheimits history only11 open or runningphase 2since Sep 22, 2026Sep 22, 2026Apr 17, 2030phase 2 · NCT07843940
DualityBio11 open or runningphase 2since Apr 9, 2025Apr 9, 2025Jun 30, 2030phase 2 · NCT06953089
  • Named in Bristol-Myers Squibb’s own pipeline as pumitamig, phase 3, as of Oct 29, 2026 (source).

Also a collaborator on its studies: MediLink Therapeutics (Suzhou), BioNTech (Shanghai) Pharmaceuticals and Genmab.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Boehringer Ingelheim and DualityBio relate to it is not in the registry or these sources.

History and studies of DualityBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2025Named pumitamigINNProposed as its International Nonproprietary Name in WHO's List 132 · before, PM8002, BNT327
  2. Apr 9, 2025First study: phase 2 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT06953089 · 750 planned · United States, Australia, China and more
  3. Jun 2, 2025Bristol Myers Squibb develops it with BioNTechCo-developmentWorldwide, profits and losses shared equally · announced · BioNTech

Ahead

  1. Jun 30, 2030Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06953089

TargetBeta

“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon adm…”NCIt, read by Claude
“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
HLX37Fosun Pharmaphase 32

Studies

The one study DualityBio leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06953089Squamous Cell Carcinoma of Head and Neck · United States, Australia, China and more2RecruitingJun 30, 2030750

How it is read

Names in the registry

  • “Pumitamig”, 18 entries
  • “PM8002”, 11 entries
  • “BNT327”, 3 entries
  • “BNT327 Dose Level 1 (DL1)”, 2 entries
  • “BNT327 Dose Level 2 (DL2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.